Following the discovery and development of a new drug, the need for strict evaluation of therapeutic effectiveness and safety before extensive clinical application is more than necessary. However, establishing complete protection of every therapeutic agent is illusory because even the finest regulatory system cannot avoid such reverses. The assessment of the balance of risks and benefits of therapy is multifactorial and requires expert, sometimes subjective, judgment. The complexities of human metabolic processes can present significant challenges in the toxicological evaluation of a new chemical entity.
On top of that, there are potential consequences of Brexit for the effectiveness of pharmaceutical research in the UK and the rest of Europe. Along with the USA, Europe is at the forefront of medicines research and has contributed hugely to past and current innovations in drug therapy. It has been highlighted that UK pharmaceutical companies are struggling to recruit talented researchers from Europe since the referendum. It is vital that those involved in the discovery and development of medicines can anticipate what the likely future regulatory requirements will be, thus providing the best chance of bringing safer, more-efficacious new treatments to market. To help organizations and leaders select the best vendors and advance their trade initiatives, Pharma Tech Outlook’s editorial board has assessed and shortlisted Drug Discovery and Development Providers that are at the forefront of providing cutting-edge technology solutions. These companies offer robust products coupled with innovative strategies that are distinctively prominent in the field. We present to you “Top 10 Drug Discovery and Development Companies in Europe - 2020.”
